|
|
Post by JHam on Jul 15, 2016 2:20:37 GMT
I totally let this one fall off of my radar. Can't believe this day has finally come, lol. Don't own any anymore and don't plan on it, even though with this much fanfare I imagine the data will be good: ir.brainstorm-cell.com/phoenix.zhtml?c=142287&p=irol-newsArticle&ID=2185604BrainStorm to Announce Top Line Results from the U.S. Phase 2 Study of NurOwn in Patients with Amyotrophic Lateral Sclerosis (ALS) on Monday, July 18 |
|
|
|
Post by morangie777 on Jul 15, 2016 4:24:06 GMT
I believe the data will disappoint high expectations. Not saying it is going to be a failure, but it will disappoint. A CEO interview a couple months ago convinced me that the data is going to be inconclusive. Everything is going to ride on the upcoming multi dose trial.
Of course for the patients I hope it is going to be spectacular data. Will be interesting.
|
|
|
|
Post by JHam on Jul 15, 2016 7:52:16 GMT
I believe the data will disappoint high expectations. Not saying it is going to be a failure, but it will disappoint. A CEO interview a couple months ago convinced me that the data is going to be inconclusive. Everything is going to ride on the upcoming multi dose trial. Of course for the patients I hope it is going to be spectacular data. Will be interesting. Good point, and you are probably right. Could be good for a nice flip today (even with the big gain yesterday), but I would be out before the data is announced just to be safe. Not worth the risk for me at the moment though. |
|
|
|
Post by JHam on Jul 18, 2016 12:16:43 GMT
|
|
|
|
Post by selluwud on Jul 18, 2016 12:21:18 GMT
|
|
|
|
Post by JHam on Jul 18, 2016 12:24:55 GMT
Ah! I was waiting for the AF response. Man he is fast  |
|
|
|
Post by selluwud on Jul 18, 2016 12:35:06 GMT
Ah! I was waiting for the AF response. Man he is fast Yep, killed the little pre-market rally. With more money needed for projected bigger trials ahead, interest is fading. |
|
|
|
Post by JHam on Jul 18, 2016 15:31:21 GMT
Ah! I was waiting for the AF response. Man he is fast Yep, killed the little pre-market rally. With more money needed for projected bigger trials ahead, interest is fading. Yeah, that was the dagger. He's right though. I still think this a promising treatment, but still a long way to go. Lebovits must be beside himself right now that this isn't over $10 today, lol. |
|
